BC Extra | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
BC Extra | Jun 7, 2018
Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Aug 11, 2017
Clinical News

Cytori's Habeo Cell Therapy misses in Phase III scleroderma trial

Cytori Therapeutics Inc. (NASDAQ:CYTX) reported top-line data from the Phase III STAR trial in 88 patients with hand dysfunction due to scleroderma showing that Habeo Cell Therapy (ECCS-50) missed the primary endpoint of improving mean...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 13, 2017
Financial News

Cytori completes follow-on

Cell therapy company Cytori Therapeutics Inc. (NASDAQ:CYTX) raised $9.5 million through the sale of 8.6 million shares at $1.10 in a follow-on underwritten by Maxim Group on April 11. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego,...
BC Week In Review | Feb 3, 2017
Company News

Azaya, Cytori deal

Cytori said it will acquire Azaya’s liposomal nanoparticle technology platform, including two cancer drugs: ATI-0918, a generic nanoparticle liposomal formulation of doxorubicin; and ATI-1123 , a liposomal encapsulated docetaxel , which has completed Phase I testing. If...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Dec 30, 2016
Financial News

Cytori financial update

Cytori entered into a 30-month stock purchase agreement with Lincoln Park Capital Fund for up to $20 million. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. ...
Items per page:
1 - 10 of 174
BC Extra | Dec 7, 2018
Company News

Management tracks: MiMedx, Akorn, Mallinckrodt

Following a spate of resignations this summer, MiMedx Group Inc. (NASDAQ:MDXG) announced three executive promotions. SVP of Strategic Initiatives Mark Landy was promoted to EVP and chief strategy officer. VP of Medical Affairs David Mason...
BC Extra | Jun 7, 2018
Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Aug 11, 2017
Clinical News

Cytori's Habeo Cell Therapy misses in Phase III scleroderma trial

Cytori Therapeutics Inc. (NASDAQ:CYTX) reported top-line data from the Phase III STAR trial in 88 patients with hand dysfunction due to scleroderma showing that Habeo Cell Therapy (ECCS-50) missed the primary endpoint of improving mean...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Apr 13, 2017
Financial News

Cytori completes follow-on

Cell therapy company Cytori Therapeutics Inc. (NASDAQ:CYTX) raised $9.5 million through the sale of 8.6 million shares at $1.10 in a follow-on underwritten by Maxim Group on April 11. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego,...
BC Week In Review | Feb 3, 2017
Company News

Azaya, Cytori deal

Cytori said it will acquire Azaya’s liposomal nanoparticle technology platform, including two cancer drugs: ATI-0918, a generic nanoparticle liposomal formulation of doxorubicin; and ATI-1123 , a liposomal encapsulated docetaxel , which has completed Phase I testing. If...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Dec 30, 2016
Financial News

Cytori financial update

Cytori entered into a 30-month stock purchase agreement with Lincoln Park Capital Fund for up to $20 million. Cytori Therapeutics Inc. (NASDAQ:CYTX), San Diego, Calif. ...
Items per page:
1 - 10 of 174